Tanezumab, and several other drugs in the family of drugs known as nerve growth factor inhibitors, are a potential breakthrough for treating osteoarthritis, back pain and other chronic pain conditions. The clinical trials for Tanezumab were halted by the FDA in 2010, because some patients were getting worse. The drug was just too good. Patients had never felt better. As a result, physical activity increased to the extent that some patients caused more damage to their joints and needed joint replacement surgery sooner than expected. Or at least that is what is believed must have happened. There was even some concern for Osteonecrosis, but that turned out to be a false alarm.
Now the drugs appear to be back on track, although the temporary halting of the trials has setback the time frame for FDA approval and then marketing.
And all good things come to an end :-(
https://rheumnow.com/news/pfizerlilly-pull-tanezumab-development?utm_source=RheumNow+Newsletter&utm_campaign=8f8209a912-EMAIL_CAMPAIGN_2021_10_26_09_04&utm_medium=email&utm_term=0_11adbca03a-8f8209a912-243777661
No comments:
Post a Comment